Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.

Management of febrile neutropenia in solid organ malignancies following chemotherapy

14 Oct 2014
72 out of 92 patients with high risk neutropenic episodes were studied. They received first-line chemotherapy for locally advanced disease. The most common microbes identified were E. coli and Staphylococcus aureus in blood, Klebsiella pneumonia in sputum and E. coli in urine culture. Cefoperazone-sulbactam was used as an initial empiric antibiotic and piperacillin/tazobactam or carbapenems were added to the patients who did not respond to initial antibiotic. Based on findings, cephaperazone-sulbactum can be an initial choice for empirical therapy in high risk febrile neutropenic patients in solid organ malignancies.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.